Coventry-based biotech, NanoSyrinx has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA.
Previous investors BioCity and the UK Innovation & Science Seed Fund (UKI2S) joined the funding round along with experienced deeptech investor IQ Capital and Jonathan Milner. The round was significantly oversubscribed with high demand both from existing and from new investors.
Transforming treatments
NanoSyrinx is the first company to engineer protein ‘nanosyringes’, a cell-selective non-viral peptide and protein delivery system. Targeted delivery of therapeutics is an important solution to improve efficacy and minimise potential side effects of existing and new treatments. NanoSyrinx’s technology has the potential to transform the treatment of a wide range of diseases. The system overcomes a number of challenges experienced in intracellular delivery such as cell specificity, payload limitations and manufacturing complexities.
The company will use…
